Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements

Mol Imaging Biol. 2017 Dec;19(6):893-902. doi: 10.1007/s11307-017-1083-9.

Abstract

Purpose: The purpose of this study is to use dynamic [18F]fluoromisonidazole ([18F]FMISO) positron emission tomography (PET) to compare estimates of tumor hypoxic fractions (HFs) derived by tracer kinetic modeling, tissue-to-blood ratios (TBR), and independent oxygen (pO2) measurements.

Procedures: BALB/c mice with EMT6 subcutaneous tumors were selected for PET imaging and invasive pO2 measurements. Data from 120-min dynamic [18F]FMISO scans were fit to two-compartment irreversible three rate constant (K 1, k 2, k 3) and Patlak models (K i). Tumor HFs were calculated and compared using K i, k 3, TBR, and pO2 values. The clinical impact of each method was evaluated on [18F]FMISO scans for three non-small cell lung cancer (NSCLC) radiotherapy patients.

Results: HFs defined by TBR (≥1.2, ≥1.3, and ≥1.4) ranged from 2 to 85 % of absolute tumor volume. HFs defined by K i (>0.004 ml min cm-3) and k 3 (>0.008 min-1) varied from 9 to 85 %. HF quantification was highly dependent on metric (TBR, k 3, or K i) and threshold. HFs quantified on human [18F]FMISO scans varied from 38 to 67, 0 to 14, and 0.1 to 27 %, for each patient, respectively, using TBR, k 3, and K i metrics.

Conclusions: [18F]FMISO PET imaging metric choice and threshold impacts hypoxia quantification reliability. Our results suggest that tracer kinetic modeling has the potential to improve hypoxia quantification clinically as it may provide a stronger correlation with direct pO2 measurements.

Keywords: Hypoxia; Pet; Quantification; Tumor; [18F]FMISO; pO2 electrode.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Hypoxia
  • Cell Line, Tumor
  • Humans
  • Kinetics
  • Male
  • Mice, Inbred BALB C
  • Misonidazole / analogs & derivatives*
  • Misonidazole / chemistry
  • Muscles / metabolism
  • Neoplasms / blood
  • Neoplasms / diagnostic imaging
  • Neoplasms / metabolism
  • Neoplasms / pathology*
  • Oxygen / metabolism*
  • Positron-Emission Tomography*
  • Tomography, X-Ray Computed
  • Tumor Burden

Substances

  • fluoromisonidazole
  • Misonidazole
  • Oxygen